The world of healthcare investments is an intriguing one, especially when we delve into the story of Cochlear Ltd. (COH), a company that has seen its share price fluctuate significantly since the start of 2025. This raises a deeper question: what makes healthcare shares so appealing to investors, and is now the time to consider adding COH to your portfolio?
The COH Story
Cochlear, founded in Sydney in 1981, is a pioneer in the medical device industry, specializing in innovative hearing solutions. With over 750,000 implantable devices delivered globally and a workforce spanning 50+ countries, the company's mission is clear: to enhance the lives of those with hearing challenges.
Why Healthcare Shares Shine
The S&P/ASX200 Healthcare Index has outperformed its broader counterpart, the ASX 200, over the last five years. Here's why healthcare shares like COH might be worth a closer look:
Sticky Revenue, Stable Returns
Healthcare spending is often considered essential, making it resilient during economic downturns. Unlike cyclical businesses, healthcare companies enjoy stable revenue streams, a phenomenon referred to as 'sticky' revenue. This stability was evident during the Global Financial Crisis, where the healthcare sector emerged as the top performer.
Growth Prospects
Global healthcare spending, particularly in the US, is projected to surge. With estimates suggesting a 7% annual growth rate from 2022 to 2027, reaching a staggering US$819 billion, the sector's potential is undeniable. Additionally, sub-sectors like healthcare IT, data solutions, and SaaS companies are forecast to grow at an impressive 15% annually from 2024 to 2030, attracting investor interest.
Ethical Investing and Healthcare
The rise of ethical and sustainable investing has positioned healthcare sectors favorably. With a focus on essential public services, healthcare companies are well-aligned with the values of ethical investors, making them an attractive investment option.
COH Share Price: A Closer Look
As a growth company, Cochlear Ltd.'s share price can be analyzed through its price-to-sales multiple. Currently, COH shares trade at a price-sales ratio of 3.65x, below its 5-year average of 9.18x. This could indicate a potential undervaluation, especially considering the company's revenue growth over the last three years. However, it's crucial to remember that investment decisions should not be based solely on one metric, and further analysis is warranted.
Final Thoughts
The healthcare sector offers a unique investment opportunity, combining stable revenue streams with growth potential. Cochlear Ltd., with its innovative hearing solutions, is a prime example of a company that could benefit from these trends. As an investor, it's essential to consider the broader context and employ a range of valuation techniques to make informed decisions. Personally, I find the intersection of healthcare and investment fascinating, and I believe it's an area worth exploring further.
